Literature DB >> 24942998

Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis.

C Wehling1, M Kirschfink.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24942998     DOI： 10.1111/jth.12639

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  4 in total

1.  Complement-mediated thrombotic microangiopathy associated with lupus nephritis.

Authors:  Mi Hee Park; Nicholas Caselman; Scott Ulmer; Ilene Ceil Weitz
Journal:  Blood Adv       Date:  2018-08-28

2.  Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.

Authors:  C Wehling; O Amon; M Bommer; B Hoppe; K Kentouche; G Schalk; R Weimer; M Wiesener; B Hohenstein; B Tönshoff; R Büscher; H Fehrenbach; Ö-N Gök; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2016-11-25       Impact factor: 4.330

3.  A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab.

Authors:  Gesa Schalk; Michael Kirschfink; Cyrill Wehling; Sara Gastoldi; Carsten Bergmann; Bernd Hoppe; Lutz T Weber
Journal:  Pediatr Nephrol       Date:  2015-03-10       Impact factor: 3.714

Review 4.  Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab.

Authors:  Kioa Lente Wijnsma; Rob Ter Heine; Dirk Jan A R Moes; Saskia Langemeijer; Saskia E M Schols; Elena B Volokhina; Lambertus P van den Heuvel; Jack F M Wetzels; Nicole C A J van de Kar; Roger J Brüggemann
Journal:  Clin Pharmacokinet       Date:  2019-07       Impact factor: 6.447
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.